The U.S. has initiated a Section 301 trade investigation into Germany, alleging the country underpays for innovative medicines. U.S. Trade Representative Jamieson Greer expressed concern over German legislative plans to reduce pharmaceutical spending, warning of potential retaliatory tariffs.
The investigation could lead to punitive tariffs on German imports, impacting trade relations between the two economic powers and potentially affecting the global pharmaceutical market.
The U.S. has launched a Section 301 trade investigation into Germany, examining allegations of underpayment for innovative pharmaceutical products. U.S. Trade Representative Jamieson Greer stated the probe will determine if Germany's practices are unreasonable or discriminatory, expressing particular concern over fast-tracked legislation aimed at reducing pharmaceutical spending. This investigation follows Germany's plan to overhaul its statutory healthcare system to address a looming funding gap of $23 billion. A docket for written comments will open on June 25, with a public hearing scheduled for September. The outcome could result in retaliatory tariffs on German imports.